Organization & Developments: Forest Labs

Parents

2011: Ironwood, Forest Seek FDA Approval (2011)
2014: The company has a deal with Forest Laboratories Inc. (NYSE: FRX) around the dementia drug MDX-8704.
Forest has well-established franchises in the therapeutic areas of the central nervous and cardiovascular systems, and is exploring new product opportunities that address a range of health conditions.
Principal brands include Lexapro®(escitalopram oxalate), Namenda®(memantine HCl), Bystolic® (nebivolol), and Savella® (milnacipran HCl)
Submitted an application to the FDA for approval of their drug linaclotide, a treatment for irritable bowel syndrome with constipation and chronic constipation.(2011)
The Clinical Data, Inc. transaction will allow Forest to extend its presence in the antidepressant category through the launch of Viibryd (vilazodone HCL tablets) which was approved by the FDA on January 21, 2011
The Company markets a portfolio of branded drug products and develops new medicines to treat patients suffering from diseases principally in five therapeutic areas: central nervous system, cardiovascular, gastrointestinal, respiratory, and anti-infective.